Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

Author Interview: Doctor David Kellner, September 2025

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA

Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash

EULAR 2025 Review Podcast

Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment

EULAR 2025 Highlights: Day 4

EULAR 2025 Highlights: Day 3

Discussing PsA: Real-world data on biologic switching and the development of EMMs

EULAR 2025 Highlights: Day 2

EULAR 2025 Highlights: Day 1

EULAR 2025 Preview Podcast

Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA